Induced pluripotency and gene editing in disease modelling: Perspectives and challenges

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28614-28634

  Seah, Yu Fen Samantha ^a   El Farran, Chadi A ^a,b   Warrier, Tushar ^a,b   Xu, Jian ^b,c   Loh, Yuin Han ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CRISPR; Disease modeling; Gene editing; IPSCs

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA 1 ANTITRYPSIN; CASPASE 9; LEUCINE RICH REPEAT KINASE 2; MICRORNA; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN 1; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; ZINC FINGER PROTEIN;

ADRENOLEUKODYSTROPHY; ALZHEIMER DISEASE; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRIGLER NAJJAR SYNDROME; DNA METHYLATION; EMBRYONIC STEM CELL; FRAGILE X SYNDROME; GENE EDITING; GENE TARGETING; GLYCOGEN STORAGE DISEASE TYPE 1; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; NUCLEAR REPROGRAMMING; PANCREAS ADENOCARCINOMA; PLURIPOTENT STEM CELL; PRADER WILLI SYNDROME; PROGERIA; TELOMERE; TRANSGENE; WILLIAMS BEUREN SYNDROME; ANIMAL; BIOLOGICAL MODEL; CRISPR CAS SYSTEM; CYTOLOGY; GENETIC ENGINEERING; INDUCED PLURIPOTENT STEM CELL; METABOLISM;

ANIMALS; CELLULAR REPROGRAMMING; CRISPR-CAS SYSTEMS; GENE TARGETING; GENETIC ENGINEERING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; TRANSGENES;

EID: 84949470075     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226119     Document Type: Article

References (149)

1. Siminovitch, L.; McCulloch, E.A.; Till, J.E. The distribution of colony-forming cells among spleen colonies. J. Cell. Comp. Physiol. 1963, 62, 327–336. [CrossRef]
2. Martin, G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 1981, 78, 7634–7638. [CrossRef] [PubMed]
3. He, S.; Nakada, D.; Morrison, S.J. Mechanisms of stem cell self-renewal. Annu. Rev. Cell Dev. Biol. 2009, 25, 377–406. [PubMed]
4. Ulloa-Montoya, F.; Verfaillie, C.M.; Hu, W.S. Culture systems for pluripotent stem cells. J. Biosci. Bioeng. 2005, 100, 12–27. [CrossRef] [PubMed]
5. Lindvall, O.; Kokaia, Z. Stem cells for the treatment of neurological disorders. Nature 2006, 441, 1094–1096. [CrossRef] [PubMed]
6. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663–676. [CrossRef] [PubMed]
7. Hanna, J.H.; Saha, K.; Jaenisch, R. Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell 2010, 143, 508–525. [CrossRef] [PubMed]
8. Brock, A.; Goh, H.T.; Yang, B.; Lu, Y.; Li, H.; Loh, Y.H. Cellular reprogramming: A new technology frontier in pharmaceutical research. Pharm. Res. 2012, 29, 35–52. [CrossRef] [PubMed]
9. Bibikova, M.; Beumer, K.; Trautman, J.K.; Carroll, D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003, 300, 764. [CrossRef] [PubMed]
10. Grizot, S.; Smith, J.; Daboussi, F.; Prieto, J.; Redondo, P.; Merino, N.; Villate, M.; Thomas, S.; Lemaire, L.; Montoya, G.; et al. Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res. 2009, 37, 5405–5419. [CrossRef] [PubMed]
11. Miller, J.C.; Tan, S.; Qiao, G.; Barlow, K.A.; Wang, J.; Xia, D.F.; Meng, X.; Paschon, D.E.; Leung, E.; Hinkley, S.J.; et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 2011, 29, 143–148. [CrossRef] [PubMed]
12. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A.; et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [CrossRef] [PubMed]
13. Sterneckert, J.L.; Reinhardt, P.; Schöler, H.R. Investigating human disease using stem cell models. Nat. Rev. Genet. 2014, 15, 625–639. [CrossRef] [PubMed]
14. Goldberg, A.D.; Allis, C.D.; Bernstein, E. Epigenetics: A landscape takes shape. Cell 2007, 128, 635–638. [CrossRef] [PubMed]
15. Loh, Y.H.; Wu, Q.; Chew, J.L.; Vega, V.B.; Zhang, W.; Chen, X.; Bourque, G.; George, J.; Leong, B.; Liu, J.; et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 2006, 38, 431–440. [CrossRef] [PubMed]
16. Gurdon, J.B. The transplantation of nuclei between two species of Xenopus. Dev. Biol. 1962, 5, 68–83. [CrossRef]
17. Okita, K.; Ichisaka, T.; Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448, 313–317. [CrossRef] [PubMed]
18. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318, 1917–1920. [CrossRef] [PubMed]
19. Maherali, N.; Ahfeldt, T.; Rigamonti, A.; Utikal, J.; Cowan, C.; Hochedlinger, K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008, 3, 340–345. [CrossRef] [PubMed]
20. Merkl, C.; Saalfrank, A.; Riesen, N.; Kühn, R.; Pertek, A.; Eser, S.; Hardt, M.S.; Kind, A.; Saur, D.; Wurst, W.; et al. Efficient generation of rat induced pluripotent stem cells using a non-viral inducible vector. PLoS ONE 2013, 8, e55170. [CrossRef] [PubMed]
21. Ichida, J.K.; Blanchard, J.; Lam, K.; Son, E.Y.; Chung, J.E.; Egli, D.; Loh, K.M.; Carter, A.C.; di Giorgio, F.P.; Koszka, K.; et al. A small-molecule inhibitor of TGF-_ signaling replaces Sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5, 491–503. [CrossRef] [PubMed]
22. Lyssiotis, C.A.; Foreman, R.K.; Staerk, J.; Garcia, M.; Mathur, D.; Markoulaki, S.; Hanna, J.; Lairson, L.L.; Charette, B.D.; Bouchez, L.C. et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf 4. Proc. Natl. Acad. Sci. USA 2009, 106, 8912–8917. [CrossRef] [PubMed]
23. Lin, T.; Ambasudhan, R.; Yuan, X.; Li, W.; Hilcove, S.; Abujarour, R.; Lin, X.; Hahm, H.S.; Hao, E.; Hayek, A.; et al. A chemical platform for improved induction of human iPSCs. Nat. Methods 2009, 6, 805–808. [CrossRef] [PubMed]
24. Zhu, S.; Li, W.; Zhou, H.; Wei, W.; Ambasudhan, R.; Lin, T.; Kim, J.; Zhang, K.; Ding, S. Reprogramming of human primary somatic cells by Oct4 and chemical compounds. Cell Stem Cell 2010, 7, 651–655. [CrossRef] [PubMed]
25. Esteban, M.A.; Wang, T.; Qin, B.; Yang, J.; Qin, D.; Cai, J.; Li, W.; Weng, Z.; Chen, J.; Ni, S.; et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010, 6, 71–79. [CrossRef] [PubMed]
26. Shi, Y.; Desponts, C.; Do, J.T.; Hahm, H.S.; Schöler, H.R.; Ding, S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3, 568–574. [CrossRef] [PubMed]
27. Huangfu, D.; Osafune, K.; Maehr, R.; Guo, W.; Eijkelenboom, A.; Chen, S.; Muhlestein, W.; Melton, D.A. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox 2. Nat. Biotechnol. 2008, 26, 1269–1275. [CrossRef] [PubMed]
28. Lin, T.; Wu, S. Reprogramming with small molecules instead of exogenous transcription factors. Stem Cells Int. 2015, 2015. [CrossRef] [PubMed]
29. Hou, P.; Li, Y.; Zhang, X.; Liu, C.; Guan, J.; Li, H.; Zhao, T.; Ye, J.; Yang, W.; Liu, K.; et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013, 341, 651–654. [CrossRef] [PubMed]
30. Okita, K.; Nakagawa, M.; Hyenjong, H.; Ichisaka, T.; Yamanaka, S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322, 949–953. [CrossRef] [PubMed]
31. Yu, J.; Hu, K.; Smuga-Otto, K.; Tian, S.; Stewart, R.; Slukvin, I.I.; Thomson, J.A. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324, 797–801. [CrossRef] [PubMed]
32. Fusaki, N.; Ban, H.; Nishiyama, A.; Saeki, K.; Hasegawa, M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009, 85, 348–362. [CrossRef] [PubMed]
33. Seki, T.; Yuasa, S.; Oda, M.; Egashira, T.; Yae, K.; Kusumoto, D.; Nakata, H.; Tohyama, S.; Hashimoto, H.; Kodaira, M.; et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010, 7, 11–14. [CrossRef] [PubMed]
34. Stadtfeld, M.; Nagaya, M.; Utikal, J.; Weir, G.; Hochedlinger, K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322, 945–949. [CrossRef] [PubMed]
35. Zhou, W.; Freed, C.R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells Dayt. Ohio 2009, 27, 2667–2674. [CrossRef] [PubMed]
36. Chang, C.W.; Lai, Y.S.; Pawlik, K.M.; Liu, K.; Sun, C.W.; Li, C.; Schoeb, T.R.; Townes, T.M. Polycistronic lentiviral vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells Dayt. Ohio 2009, 27, 1042–1049. [CrossRef] [PubMed]
37. Sommer, A.G.; Rozelle, S.S.; Sullivan, S.; Mills, J.A.; Park, S.M.; Smith, B.W.; Iyer, A.M.; French, D.L.; Kotton, D.N.; Gadue, P.; et al. Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. J. Vis. Exp. 2012. [CrossRef] [PubMed]
38. Yusa, K.; Rad, R.; Takeda, J.; Bradley, A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBAC transposon. Nat. Methods 2009, 6, 363–369. [CrossRef] [PubMed]
39. Warren, L.; Manos, P.D.; Ahfeldt, T.; Loh, Y.H.; Li, H.; Lau, F.; Ebina, W.; Mandal, P.K.; Smith, Z.D.; Meissner, A.; et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7, 618–630. [CrossRef] [PubMed]
40. Plews, J.R.; Li, J.; Jones, M.; Moore, H.D.; Mason, C.; Andrews, P.W.; Na, J. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS ONE 2010, 5, e14397. [CrossRef] [PubMed]
41. Zhou, H.; Wu, S.; Joo, J.Y.; Zhu, S.; Han, D.W.; Lin, T.; Trauger, S.; Bien, G.; Yao, S.; Zhu, Y.; et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4, 381–384. [CrossRef] [PubMed]
42. Kim, D.; Kim, C.H.; Moon, J.I.; Chung, Y.G.; Chang, M.Y.; Han, B.S.; Ko, S.; Yang, E.; Cha, K.Y.; Lanza, R.; et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4, 472–476. [CrossRef] [PubMed]
43. Lee, C.H.; Kim, J.H.; Lee, H.J.; Jeon, K.; Lim, H.; Choi, H.; Lee, E.R.; Park, S.H.; Park, J.Y.; Hong, S.; et al. The generation of iPS cells using non-viral magnetic nanoparticle based transfection. Biomaterials 2011, 32, 6683–6691. [CrossRef] [PubMed]
44. Anokye-Danso, F.; Trivedi, C.M.; Juhr, D.; Gupta, M.; Cui, Z.; Tian, Y.; Zhang, Y.; Yang, W.; Gruber, P.J.; Epstein, J.A.; et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8, 376–388. [CrossRef] [PubMed]
45. Hanna, J.; Markoulaki, S.; Schorderet, P.; Carey, B.W.; Beard, C.; Wernig, M.; Creyghton, M.P.; Steine, E.J.; Cassady, J.P.; Foreman, R.; et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008, 133, 250–264. [CrossRef] [PubMed]
46. Eminli, S.; Utikal, J.; Arnold, K.; Jaenisch, R.; Hochedlinger, K. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells Dayt. Ohio 2008, 26, 2467–2474. [CrossRef] [PubMed]
47. Aoki, T.; Ohnishi, H.; Oda, Y.; Tadokoro, M.; Sasao, M.; Kato, H.; Hattori, K.; Ohgushi, H. Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-MYC. Tissue Eng. Part A 2010, 16, 2197–2206. [CrossRef] [PubMed]
48. Aasen, T.; Raya, A.; Barrero, M.J.; Garreta, E.; Consiglio, A.; Gonzalez, F.; Vassena, R.; Bilić, J.; Pekarik, V.; Tiscornia, G.; et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 2008, 26, 1276–1284. [CrossRef] [PubMed]
49. Loh, Y.H.; Hartung, O.; Li, H.; Guo, C.; Sahalie, J.M.; Manos, P.D.; Urbach, A.; Heffner, G.C.; Grskovic, M.; Vigneault, F.; et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell 2010, 7, 15–19. [CrossRef] [PubMed]
50. Staerk, J.; Dawlaty, M.M.; Gao, Q.; Maetzel, D.; Hanna, J.; Sommer, C.A.; Mostoslavsky, G.; Jaenisch, R. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 2010, 7, 20–24. [CrossRef] [PubMed]
51. Wang, Y.; Liu, J.; Tan, X.; Li, G.; Gao, Y.; Liu, X.; Zhang, L.; Li, Y. Induced pluripotent stem cells from human hair follicle mesenchymal stem cells. Stem Cell Rev. 2013, 9, 451–460. [CrossRef] [PubMed]
52. Li, Q.; Fan, Y.; Sun, X.; Yu, Y. Generation of induced pluripotent stem cells from human amniotic fluid cells by reprogramming with two factors in feeder-free conditions. J. Reprod. Dev. 2013, 59, 72–77. [CrossRef] [PubMed]
53. Ruiz, S.; Brennand, K.; Panopoulos, A.D.; Herrerías, A.; Gage, F.H.; Izpisua-Belmonte, J.C. High-efficient generation of induced pluripotent stem cells from human astrocytes. PLoS ONE 2010, 5, e15526. [CrossRef] [PubMed]
54. Park, I.H.; Zhao, R.; West, J.A.; Yabuuchi, A.; Huo, H.; Ince, T.A.; Lerou, P.H.; Lensch, M.W.; Daley, G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451, 141–146. [CrossRef] [PubMed]
55. Bibikova, M.; Golic, M.; Golic, K.G.; Carroll, D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002, 161, 1169–1175. [PubMed]
56. Perez, E.E.; Wang, J.; Miller, J.C.; Jouvenot, Y.; Kim, K.A.; Liu, O.; Wang, N.; Lee, G.; Bartsevich, V.V.; Lee, Y.L.; et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26, 808–816. [CrossRef] [PubMed]
57. Bibikova, M.; Carroll, D.; Segal, D.J.; Trautman, J.K.; Smith, J.; Kim, Y.G.; Chandrasegaran, S. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol. Cell. Biol. 2001, 21, 289–297. [CrossRef] [PubMed]
58. Rong, Z.; Zhu, S.; Xu, Y.; Fu, X. Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. Protein Cell 2014, 5, 258–260. [CrossRef] [PubMed]
59. Smith, J.; Grizot, S.; Arnould, S.; Duclert, A.; Epinat, J.C.; Chames, P.; Prieto, J.; Redondo, P.; Blanco, F.J.; Bravo, J.; et al. A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res. 2006, 34, e149. [CrossRef] [PubMed]
60. Liu, J.; Stormo, G.D. Context-dependent DNA recognition code for C2H2 zinc-finger transcription factors. Bioinform. Oxf. Engl. 2008, 24, 1850–1857. [CrossRef] [PubMed]
61. Durai, S.; Mani, M.; Kandavelou, K.; Wu, J.; Porteus, M.H.; Chandrasegaran, S. Zinc finger nucleases: Custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 2005, 33, 5978–5990. [CrossRef] [PubMed]
62. Li, T.; Yang, B. TAL effector nuclease (TALEN) engineering. Methods Mol. Biol. 2013, 978, 63–72. [PubMed]
63. Gogarten, J.P.; Hilario, E. Inteins, introns, and homing endonucleases: Recent revelations about the life cycle of parasitic genetic elements. BMC Evol. Biol. 2006, 6, 94. [CrossRef] [PubMed]
64. Cox, D.B.T.; Platt, R.J.; Zhang, F. Therapeutic genome editing: Prospects and challenges. Nat. Med. 2015, 21, 121–131. [CrossRef] [PubMed]
65. Silva, G.; Poirot, L.; Galetto, R.; Smith, J.; Montoya, G.; Duchateau, P.; Paques, F. Meganucleases and other tools for targeted genome engineering: Perspectives and challenges for gene therapy. Curr. Gene Ther. 2011, 11, 11–27. [CrossRef] [PubMed]
66. Cathomen, T.; Joung, J.K. Zinc-finger nucleases: The next generation emerges. Mol. Ther. J. Am. Soc. Gene Ther. 2008, 16, 1200–1207. [CrossRef] [PubMed]
67. Kim, Y.G.; Cha, J.; Chandrasegaran, S. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 1996, 93, 1156–1160. [CrossRef] [PubMed]
68. Ramirez, C.L.; Foley, J.E.; Wright, D.A.; Müller-Lerch, F.; Rahman, S.H.; Cornu, T.I.; Winfrey, R.J.; Sander, J.D.; Fu, F.; Townsend, J.A.; et al. Unexpected failure rates for modular assembly of engineered zinc fingers. Nat. Methods 2008, 5, 374–375. [CrossRef] [PubMed]
69. Christian, M.; Cermak, T.; Doyle, E.L.; Schmidt, C.; Zhang, F.; Hummel, A.; Bogdanove, A.J.; Voytas, D.F. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186, 757–761. [CrossRef] [PubMed]
70. Reyon, D.; Tsai, S.Q.; Khayter, C.; Foden, J.A.; Sander, J.D.; Joung, J.K. FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 2012, 30, 460–465. [CrossRef] [PubMed]
71. Carlson, D.F.; Fahrenkrug, S.C.; Hackett, P.B. Targeting DNA with fingers and TALENs. Mol. Ther. Nucleic Acids 2012, 1, e3. [CrossRef] [PubMed]
72. Barrangou, R.; Fremaux, C.; Deveau, H.; Richards, M.; Boyaval, P.; Moineau, S.; Romero, D.A.; Horvath, P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315, 1709–1712. [CrossRef] [PubMed]
73. Wang, H.; Yang, H.; Shivalila, C.S.; Dawlaty, M.M.; Cheng, A.W.; Zhang, F.; Jaenisch, R. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013, 153, 910–918. [CrossRef] [PubMed]
74. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A Programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337, 816–821. [CrossRef] [PubMed]
75. Fu, Y.; Foden, J.A.; Khayter, C.; Maeder, M.L.; Reyon, D.; Joung, J.K.; Sander, J.D. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 2013, 31, 822–826. [CrossRef] [PubMed]
76. Ishino, Y.; Shinagawa, H.; Makino, K.; Amemura, M.; Nakata, A. Nucleotide sequence of the IAP gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 1987, 169, 5429–5433. [PubMed]
77. Mojica, F.J.M.; Díez-Villaseñor, C.; García-Martínez, J.; Soria, E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 2005, 60, 174–182. [CrossRef] [PubMed]
78. Mali, P.; Yang, L.; Esvelt, K.M.; Aach, J.; Guell, M.; di Carlo, J.E.; Norville, J.E.; Church, G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339, 823–826. [CrossRef] [PubMed]
79. Garneau, J.E.; Dupuis, M.È.; Villion, M.; Romero, D.A.; Barrangou, R.; Boyaval, P.; Fremaux, C.; Horvath, P.; Magadán, A.H.; Moineau, S. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 2010, 468, 67–71. [CrossRef] [PubMed]
80. Ran, F.A.; Hsu, P.D.; Lin, C.Y.; Gootenberg, J.S.; Konermann, S.; Trevino, A.E.; Scott, D.A.; Inoue, A.; Matoba, S.; Zhang, Y.; et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154, 1380–1389. [CrossRef] [PubMed]
81. Mali, P.; Aach, J.; Stranges, P.B.; Esvelt, K.M.; Moosburner, M.; Kosuri, S.; Yang, L.; Church, G.M. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 2013, 31, 833–838. [CrossRef] [PubMed]
82. Meyer, M.; Ortiz, O.; Hrabé de Angelis, M.; Wurst, W.; Kühn, R. Modeling disease mutations by gene targeting in one-cell mouse embryos. Proc. Natl. Acad. Sci. USA 2012, 109, 9354–9359. [CrossRef] [PubMed]
83. Soldner, F.; Laganiere, J.; Cheng, A.W.; Hockemeyer, D.; Gao, Q.; Alagappan, R.; Khurana, V.; Golbe, L.I.; Myers, R.H.; Lindquist, S.; et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146, 318–331. [CrossRef] [PubMed]
84. Bellin, M.; Casini, S.; Davis, R.P.; Aniello, C.D.; Haas, J.; Ward-van Oostwaard, D.; Tertoolen, L.G.J.; Jung, C.B.; Elliott, D.A.; Welling, A.; et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013, 32, 3161–3175. [CrossRef] [PubMed]
85. Egashira, T.; Yuasa, S.; Fukuda, K. Novel insights into disease modeling using induced pluripotent stem cells. Biol. Pharm. Bull. 2013, 36, 182–188. [CrossRef] [PubMed]
86. Egashira, T.; Yuasa, S.; Suzuki, T.; Aizawa, Y.; Yamakawa, H.; Matsuhashi, T.; Ohno, Y.; Tohyama, S.; Okata, S.; Seki, T.; et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 2012, 95, 419–429. [CrossRef] [PubMed]
87. Shefner, J.M.; Cudkowicz, M.E.; Schoenfeld, D.; Conrad, T.; Taft, J.; Chilton, M.; Urbinelli, L.; Qureshi, M.; Zhang, H.; Pestronk, A.; et al. NEALS Consortium. A clinical trial of creatine in ALS. Neurology 2004, 63, 1656–1661. [CrossRef] [PubMed]
88. Singh, B.; Gupta, R.S. Species-specific differences in the toxicity and mutagenicity of the anticancer drugs mithramycin, chromomycin A3, and olivomycin. Cancer Res. 1985, 45, 2813–2820. [PubMed]
89. Chun, Y.S. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int. J. Biol. Sci. 2010, 796–805. [CrossRef]
90. Gore, A.; Li, Z.; Fung, H.L.; Young, J.E.; Agarwal, S.; Antosiewicz-Bourget, J.; Canto, I.; Giorgetti, A.; Israel, M.A.; Kiskinis, E.; et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471, 63–67. [CrossRef] [PubMed]
91. Ohi, Y.; Qin, H.; Hong, C.; Blouin, L.; Polo, J.M.; Guo, T.; Qi, Z.; Downey, S.L.; Manos, P.D.; Rossi, D.J.; et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat. Cell Biol. 2011, 13, 541–549. [CrossRef] [PubMed]
92. Laurent, L.C.; Ulitsky, I.; Slavin, I.; Tran, H.; Schork, A.; Morey, R.; Lynch, C.; Harness, J.V.; Lee, S.; Barrero, M.J.; et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8, 106–118. [CrossRef] [PubMed]
93. Mekhoubad, S.; Bock, C.; de Boer, A.S.; Kiskinis, E.; Meissner, A.; Eggan, K. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 2012, 10, 595–609. [CrossRef] [PubMed]
94. Moad, M.; Pal, D.; Hepburn, A.C.; Williamson, S.C.; Wilson, L.; Lako, M.; Armstrong, L.; Hayward, S.W.; Franco, O.E.; Cates, J.M.; et al. A novel model of urinary tract differentiation, tissue regeneration, and disease: Reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur. Urol. 2013, 64, 753–761. [CrossRef] [PubMed]
95. Nguyen, H.N.; Byers, B.; Cord, B.; Shcheglovitov, A.; Byrne, J.; Gujar, P.; Kee, K.; Schüle, B.; Dolmetsch, R.E.; Langston, W.; et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011, 8, 267–280. [CrossRef] [PubMed]
96. Israel, M.A.; Yuan, S.H.; Bardy, C.; Reyna, S.M.; Mu, Y.; Herrera, C.; Hefferan, M.P.; van Gorp, S.; Nazor, K.L.; Boscolo, F.S.; et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 2012, 482, 216–220. [CrossRef] [PubMed]
97. Dimos, J.T.; Rodolfa, K.T.; Niakan, K.K.; Weisenthal, L.M.; Mitsumoto, H.; Chung, W.; Croft, G.F.; Saphier, G.; Leibel, R.; Goland, R.; et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321, 1218–1221. [CrossRef] [PubMed]
98. Ebert, A.D.; Yu, J.; Rose, F.F.; Mattis, V.B.; Lorson, C.L.; Thomson, J.A.; Svendsen, C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457, 277–280. [CrossRef] [PubMed]
99. Juopperi, T.A.; Kim, W.R.; Chiang, C.H.; Yu, H.; Margolis, R.L.; Ross, C.A.; Ming, G.; Song, H. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells. Mol. Brain 2012, 5, 17. [CrossRef] [PubMed]
100. Sheridan, S.D.; Theriault, K.M.; Reis, S.A.; Zhou, F.; Madison, J.M.; Daheron, L.; Loring, J.F.; Haggarty, S.J. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 2011, 6, e26203. [CrossRef] [PubMed]
101. Wang, X.M.; Yik, W.Y.; Zhang, P.; Lu, W.; Dranchak, P.K.; Shibata, D.; Steinberg, S.J.; Hacia, J.G. The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesis. Stem Cell Res. Ther. 2012, 3, 39. [CrossRef] [PubMed]
102. Lu, H.E.; Yang, Y.C.; Chen, S.M.; Su, H.L.; Huang, P.C.; Tsai, M.S.; Wang, T.H.; Tseng, C.P.; Hwang, S.M. Modeling neurogenesis impairment in Down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells. Exp. Cell Res. 2013, 319, 498–505. [CrossRef] [PubMed]
103. Batista, L.F.Z.; Pech, M.F.; Zhong, F.L.; Nguyen, H.N.; Xie, K.T.; Zaug, A.J.; Crary, S.M.; Choi, J.; Sebastiano, V.; Cherry, A.; et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011, 474, 399–402. [CrossRef] [PubMed]
104. Ku, S.; Soragni, E.; Campau, E.; Thomas, E.A.; Altun, G.; Laurent, L.C.; Loring, J.F.; Napierala, M.; Gottesfeld, J.M. Friedreich’s ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 2010, 7, 631–637. [CrossRef] [PubMed]
105. Fujikura, J.; Nakao, K.; Sone, M.; Noguchi, M.; Mori, E.; Naito, M.; Taura, D.; Harada-Shiba, M.; Kishimoto, I.; Watanabe, A.; et al. Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia 2012, 55, 1689–1698. [CrossRef] [PubMed]
106. Jiang, Y.; Cowley, S.A.; Siler, U.; Melguizo, D.; Tilgner, K.; Browne, C.; Dewilton, A.; Przyborski, S.; Saretzki, G.; James, W.S.; et al. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells Dayt. Ohio 2012, 30, 599–611. [CrossRef] [PubMed]
107. Kumano, K.; Arai, S.; Hosoi, M.; Taoka, K.; Takayama, N.; Otsu, M.; Nagae, G.; Ueda, K.; Nakazaki, K.; Kamikubo, Y.; et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012, 119, 6234–6242. [CrossRef] [PubMed]
108. Müller, L.U.W.; Schlaeger, T.M.; de Vine, A.L.; Williams, D.A. Induced pluripotent stem cells as a tool for gaining new insights into Fanconi anemia. Cell Cycle Georget. Tex 2012, 11, 2985–2990. [CrossRef] [PubMed]
109. Rashid, S.T.; Corbineau, S.; Hannan, N.; Marciniak, S.J.; Miranda, E.; Alexander, G.; Huang-Doran, I.; Griffin, J.; Ahrlund-Richter, L.; Skepper, J.; et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Investig. 2010, 120, 3127–3136. [CrossRef] [PubMed]
110. Yang, J.; Cai, J.; Zhang, Y.; Wang, X.; Li, W.; Xu, J.; Li, F.; Guo, X.; Deng, K.; Zhong, M.; et al. Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J. Biol. Chem. 2010, 285, 40303–40311. [CrossRef] [PubMed]
111. Chamberlain, S.J.; Chen, P.F.; Ng, K.Y.; Bourgois-Rocha, F.; Lemtiri-Chlieh, F.; Levine, E.S.; Lalande, M. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc. Natl. Acad. Sci. USA 2010, 107, 17668–17673. [CrossRef] [PubMed]
112. Moretti, A.; Bellin, M.; Welling, A.; Jung, C.B.; Lam, J.T.; Bott-Flügel, L.; Dorn, T.; Goedel, A.; Höhnke, C.; Hofmann, F.; et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363, 1397–1409. [CrossRef] [PubMed]
113. Itzhaki, I.; Maizels, L.; Huber, I.; Zwi-Dantsis, L.; Caspi, O.; Winterstern, A.; Feldman, O.; Gepstein, A.; Arbel, G.; Hammerman, H.; et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471, 225–229. [CrossRef] [PubMed]
114. Yazawa, M.; Hsueh, B.; Jia, X.; Pasca, A.M.; Bernstein, J.A.; Hallmayer, J.; Dolmetsch, R.E. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471, 230–234. [CrossRef] [PubMed]
115. Carvajal-Vergara, X.; Sevilla, A.; Souza, S.L.D.; Ang, Y.S.; Schaniel, C.; Lee, D.F.; Yang, L.; Kaplan, A.D.; Adler, E.D.; Rozov, R.; et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465, 808–812. [CrossRef] [PubMed]
116. Zhang, J.; Lian, Q.; Zhu, G.; Zhou, F.; Sui, L.; Tan, C.; Mutalif, R.A.; Navasankari, R.; Zhang, Y.; Tse, H.F.; et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011, 8, 31–45. [CrossRef] [PubMed]
117. Itzhaki, I.; Maizels, L.; Huber, I.; Gepstein, A.; Arbel, G.; Caspi, O.; Miller, L.; Belhassen, B.; Nof, E.; Glikson, M.; et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J. Am. Coll. Cardiol. 2012, 60, 990–1000. [CrossRef] [PubMed]
118. Sun, N.; Yazawa, M.; Liu, J.; Han, L.; Sanchez-Freire, V.; Abilez, O.J.; Navarrete, E.G.; Hu, S.; Wang, L.; Lee, A.; et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 2012, 4, 130ra47. [CrossRef] [PubMed]
119. Kinnear, C.; Chang, W.Y.; Khattak, S.; Hinek, A.; Thompson, T.; de Carvalho Rodrigues, D.; Kennedy, K.; Mahmut, N.; Pasceri, P.; Stanford, W.L.; et al. Modeling and rescue of the vascular phenotype of Williams-Beuren syndrome in patient induced pluripotent stem cells. Stem Cells Transl. Med. 2013, 2, 2–15. [CrossRef] [PubMed]
120. Jin, Z.B.; Okamoto, S.; Osakada, F.; Homma, K.; Assawachananont, J.; Hirami, Y.; Iwata, T.; Takahashi, M. Modeling retinal degeneration using patient-specific induced pluripotent stem cells. PLoS ONE 2011, 6, e17084. [CrossRef] [PubMed]
121. Chen, Y.; Luo, R.; Xu, Y.; Cai, X.; Li, W.; Tan, K.; Huang, J.; Dai, Y. Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine. Rheumatol. Int. 2013, 33, 2127–2134. [CrossRef] [PubMed]
122. Saitta, B.; Passarini, J.; Sareen, D.; Ornelas, L.; Sahabian, A.; Argade, S.; Krakow, D.; Cohn, D.H.; Svendsen, C.N.; Rimoin, D.L. Patient-derived skeletal dysplasia induced pluripotent stem cells display abnormal chondrogenic marker expression and regulation by BMP2 and TGFβ1. Stem Cells Dev. 2014, 23, 1464–1478. [CrossRef] [PubMed]
123. Lee, D.F.; Su, J.; Kim, H.S.; Chang, B.; Papatsenko, D.; Zhao, R.; Yuan, Y.; Gingold, J.; Xia,W.; Darr, H.; et al. Modeling familial cancer with induced pluripotent stem cells. Cell 2015, 161, 240–254. [CrossRef] [PubMed]
124. Singh, V.K.; Kalsan, M.; Kumar, N.; Saini, A.; Chandra, R. Induced pluripotent stem cells: Applications in regenerative medicine, disease modeling, and drug discovery. Front. Cell Dev. Biol. 2015, 3, 2. [CrossRef] [PubMed]
125. Ghodsizadeh, A.; Taei, A.; Totonchi, M.; Seifinejad, A.; Gourabi, H.; Pournasr, B.; Aghdami, N.; Malekzadeh, R.; Almadani, N.; Salekdeh, G.H.; et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev. 2010, 6, 622–632. [CrossRef] [PubMed]
126. Choi, S.M.; Kim, Y.; Shim, J.S.; Park, J.T.; Wang, R.H.; Leach, S.D.; Liu, J.O.; Deng, C.; Ye, Z.; Jang, Y.Y. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013, 57, 2458–2468. [CrossRef] [PubMed]
127. Irudayam, J.I. Modeling Liver Diseases Using Induced Pluripotent Stem Cell (Ipsc)-Derived Hepatocytes. J. Stem Cell Res. Ther. 2014, 4, 218. [CrossRef]
128. Ye, Z.; Zhan, H.; Mali, P.; Dowey, S.; Williams, D.M.; Jang, Y.Y.; Dang, C.V.; Spivak, J.L.; Moliterno, A.R.; Cheng, L. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009, 114, 5473–5480. [CrossRef] [PubMed]
129. Trevisan, M.; Sinigaglia, A.; Desole, G.; Berto, A.; Pacenti, M.; Palù, G.; Barzon, L. Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses 2015, 7, 3835–3856. [CrossRef] [PubMed]
130. Lafaille, F.G.; Pessach, I.M.; Zhang, S.Y.; Ciancanelli, M.J.; Herman, M.; Abhyankar, A.; Ying, S.W.; Keros, S.; Goldstein, P.A.; Mostoslavsky, G.; et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012, 491, 769–773. [CrossRef] [PubMed]
131. Ciancanelli, M.J.; Huang, S.X.L.; Luthra, P.; Garner, H.; Itan, Y.; Volpi, S.; Lafaille, F.G.; Trouillet, C.; Schmolke, M.; Albrecht, R.A.; et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 2015, 348, 448–453. [CrossRef] [PubMed]
132. Kambal, A.; Mitchell, G.; Cary, W.; Gruenloh, W.; Jung, Y.; Kalomoiris, S.; Nacey, C.; McGee, J.; Lindsey, M.; Fury, B.; et al. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol. Ther. J. Am. Soc. Gene Ther. 2011, 19, 584–593. [CrossRef] [PubMed]
133. Kaur, G.; Dufour, J.M. Cell lines: Valuable tools or useless artifacts. Spermatogenesis 2012, 2, 1–5. [CrossRef] [PubMed]
134. Kim, J.; Hoffman, J.P.; Alpaugh, R.K.; Rhim, A.D.; Rhimm, A.D.; Reichert, M.; Stanger, B.Z.; Furth, E.E.; Sepulveda, A.R.; Yuan, C.X.; et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 2013, 3, 2088–2099. [CrossRef] [PubMed]
135. Riggs, J.W.; Barrilleaux, B.L.; Varlakhanova, N.; Bush, K.M.; Chan, V.; Knoepfler, P.S. Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev. 2013, 22, 37–50. [CrossRef] [PubMed]
136. Curry, E.L.; Moad, M.; Robson, C.N.; Heer, R. Using induced pluripotent stem cells as a tool for modelling carcinogenesis. World J. Stem Cells 2015, 7, 461–469. [CrossRef] [PubMed]
137. Wong, D.J.; Liu, H.; Ridky, T.W.; Cassarino, D.; Segal, E.; Chang, H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2, 333–344. [CrossRef] [PubMed]
138. Kim, K.; Doi, A.; Wen, B.; Ng, K.; Zhao, R.; Cahan, P.; Kim, J.; Aryee, M.J.; Ji, H.; Ehrlich, L.I.R.; et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467, 285–290. [CrossRef] [PubMed]
139. Osafune, K.; Caron, L.; Borowiak, M.; Martinez, R.J.; Fitz-Gerald, C.S.; Sato, Y.; Cowan, C.A.; Chien, K.R.; Melton, D.A. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat. Biotechnol. 2008, 26, 313–315. [CrossRef] [PubMed]
140. Soldner, F.; Jaenisch, R. iPSC disease modeling. Science 2012, 338, 1155–1156. [CrossRef] [PubMed]
141. Soldner, F.; Hockemeyer, D.; Beard, C.; Gao, Q.; Bell, G.W.; Cook, E.G.; Hargus, G.; Blak, A.; Cooper, O.; Mitalipova, M.; et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136, 964–977. [CrossRef] [PubMed]
142. Meissner, A. Epigenetic modifications in pluripotent and differentiated cells. Nat. Biotechnol. 2010, 28, 1079–1088. [CrossRef] [PubMed]
143. Takebe, T.; Sekine, K.; Enomura, M.; Koike, H.; Kimura, M.; Ogaeri, T.; Zhang, R.R.; Ueno, Y.; Zheng, Y.W.; Koike, N.; et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013, 499, 481–484. [CrossRef] [PubMed]
144. Lancaster, M.A.; Renner, M.; Martin, C.A.; Wenzel, D.; Bicknell, L.S.; Hurles, M.E.; Homfray, T.; Penninger, J.M.; Jackson, A.P.; Knoblich, J.A. Cerebral organoids model human brain development and microcephaly. Nature 2013, 501, 373–379. [CrossRef] [PubMed]
145. Zhang, D.; Pekkanen-Mattila, M.; Shahsavani, M.; Falk, A.; Teixeira, A.I.; Herland, A. A 3D Alzheimer’s disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. Biomaterials 2014, 35, 1420–1428. [CrossRef] [PubMed]
146. Eiraku, M.; Takata, N.; Ishibashi, H.; Kawada, M.; Sakakura, E.; Okuda, S.; Sekiguchi, K.; Adachi, T.; Sasai, Y. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 2011, 472, 51–56. [CrossRef] [PubMed]
147. Xia, Y.; Sancho-Martinez, I.; Nivet, E.; Rodriguez Esteban, C.; Campistol, J.M.; Izpisua Belmonte, J.C. The generation of kidney organoids by differentiation of human pluripotent cells to ureteric bud progenitor-like cells. Nat. Protoc. 2014, 9, 2693–2704. [CrossRef] [PubMed]
148. Miller, J.D.; Ganat, Y.M.; Kishinevsky, S.; Bowman, R.L.; Liu, B.; Tu, E.Y.; Mandal, P.K.; Vera, E.; Shim, J.; Kriks, S.; et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 2013, 13, 691–705. [CrossRef] [PubMed]
149. Koch, P.; Breuer, P.; Peitz, M.; Jungverdorben, J.; Kesavan, J.; Poppe, D.; Doerr, J.; Ladewig, J.; Mertens, J.; Tüting, T.; et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011, 480, 543–546. [CrossRef] [PubMed]